GOVX

GeoVax Labs, Inc. operates as a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for infectious diseases and cancer. Headquartered in Smyrna, Georgia, the company utilizes its proprietary Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform technology to create next-generation vaccines. GeoVax's pipeline includes vaccine candidates targeting preventable diseases such as COVID-19, monkeypox, hemorrhagic fever viruses including Ebola, Marburg, and Lassa fever, as well as malaria and human immunodeficiency virus (HIV). The company's platform technology is designed to elicit durable cellular and humoral immune responses by mimicking a natural infection. GeoVax has conducted multiple clinical trials and maintains collaborative relationships with government agencies including the National Institutes of Health and the Centers for Disease Control and Prevention. The company has received funding support from various U.S. government contracts and grants for vaccine development programs. In recent developments, GeoVax has advanced its Gedeptin® immunotherapy program for solid tumors and continues clinical evaluation of its preventive vaccine candidates. As a publicly traded company on the Nasdaq Capital Market under the ticker GOVX, GeoVax employs approximately 15 full-time staff members and leverages partnerships with contract research organizations and manufacturing partners to advance its development programs.